In this issue:
Tisagenlecleucel in R/R DLBCL
Ibrutinib vs chemoimmunotherapy in CLL
Immune escape of relapsed AML cells
Brentuximab vedotin plus chemo for PTCL
Cause of death in the rituximab era
MRD-guided treatment with azacitidine
EPOCH-R in DLBCL with MYC rearrangement
Hyper-CVAD + ponatinib in ALL
HBV reactivation with immunochemotherapy
Venetoclax + decitabine or azacitidine in AM
Please login below to download this issue (PDF)